Regenxbio Inc. priced its underwritten public offering of common shares to raise $175.5 million in gross proceeds.

The gene therapy company will offer 2,700,000 shares at $65 per share and has granted the underwriters a 30-day option to purchase additional 405,000 shares to cover overallotments if any.

The offering is expected to close on or about Aug. 14, subject to customary closing conditions.

Rockville, Md.-based Regenxbio uses its NAV technology platform, an adeno-associated virus gene delivery platform, to engineer product candidates for the treatment of retinal, metabolic and neurodegenerative diseases.